Follow Us on StockTwits

Institutional Traders Buying Eleven Biotherapeutics

Posted by on January 7, 2017 2:45 PM
Tags: , , , , , ,
Categories: Stocks

January 7, 2017: According to 13F filings, institutional traders are accumulating Eleven Biotherapeutics. Firms that bought shares according to their most recent 13F filings are: Flagship Ventures Management, Blackrock Institutional Trust, VANGUARD GROUP, MILLENNIUM MANAGEMENT, Bank of New York Mellon, Dynamic Technology, SUSQUEHANNA INTERNATIONAL, KCG Holdings, PRICE T ROWE, and many more.

Revenue YOY is up an incredible 42,661.19%.

Eleven Biotherapeutics Stock Chart

Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of anti-cancer agents based on Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven’s proprietary one-step manufacturing process.


Follow me

Lance Jepsen

For ethical purposes, I try not to hold any position in any stock I profile on unless specifically stated in the article. Owner of Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.
Follow me